预约演示
更新于：2026-03-27
Perindopril/Indapamide
培哚普利吲达帕胺
更新于：2026-03-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C35H48ClN5O8S |
InChIKeyLRRJSCKXFJTRLC-MHXJNQAMSA-N |
CAS号182176-83-6 |
关联
14
项与 培哚普利吲达帕胺 相关的临床试验CTR20250879
培哚普利吲达帕胺片在健康研究参与者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后生物等效性试验
CTR20250386
随机、开放、单剂量、两制剂、两序列、交叉对照设计，评价空腹及餐后状态下单次口服受试制剂培哚普利吲达帕胺片与参比制剂培哚普利吲达帕胺片（商品名：百普乐®）在中国健康受试者中的生物等效性正式试验
CTR20231821
培哚普利吲达帕胺片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后状态下生物等效性试验
100 项与 培哚普利吲达帕胺 相关的临床结果
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的转化医学
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的专利（医药）
登录后查看更多信息
128
项与 培哚普利吲达帕胺 相关的文献（医药）2025-05-01BMJ Open Diabetes Research & Care
Relationship between time-varying achieved HbA1c and risk of coronary artery disease events among common haptoglobin phenotype groups with type 2 diabetes: the ADVANCE study
Article
作者: Woodward, Mark ; Mancia, Giuseppe ; Marre, Michel ; Sapp, John ; Carew, Allie S ; Samuel, Michelle ; Harris, Katie ; Warren, Rachel A ; Chalmers, John ; Selvin, Elizabeth ; Lavallée, Samantha K ; Rimm, Eric ; Levy, Andrew P ; Harrap, Stephen ; Cahill, Leah E ; Poulter, Neil
Introduction:
This study sought to determine whether the association between attaining specific glycated hemoglobin (HbA1c) targets (<7.0% (<53 mmol/mol) and ≥8.0% (≥64 mmol/mol) compared with 7.0%–7.9%) over time and risk of incident coronary artery disease (CAD) was dependent on haptoglobin (Hp) phenotype in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study.
Research design and methods:
Prospectively collected HbA1c data from the ADVANCE biomarker case-cohort study, updated at 6 months and every 12 months thereafter over a median of 5.0 (IQR 4.5–5.3) years, were analyzed in relation to incident CAD in the Hp2-2 (n=1323) and non-Hp2-2 (n=2069) phenotypes separately using weighted multivariable-adjusted Cox regression models. Additional a priori stratifications by sex, race, previous cardiovascular disease (CVD), and type 2 diabetes duration were performed.
Results:
Mean HbA1c was similar in each phenotype group throughout the study. Compared with HbA1c of 7.0%–7.9%, HbA1c <7.0% was not associated with CAD risk for any phenotype group or subgroup. HbA1c ≥8.0% compared with 7.0%–7.9% over time was associated with higher CAD risk for the Hp2-2 phenotype only (HR 1.53, 95% CI 1.01 to 2.32; no significant association in the non-Hp2-2 type: 1.26, 0.89 to 1.77, p-interaction=0.71); this was pronounced when those with previous CVD at baseline were excluded (Hp2-2: 2.80, 1.41 to 5.53, p-interaction=0.03). Compared with HbA1c of <8.0%, having HbA1c ≥8.0% was associated with a 59% higher CAD risk among participants with the Hp2-2 phenotype (1.59, 1.12 to 2.26) and a 39% higher CAD risk among participants without the Hp2-2 phenotype (1.39, 1.03 to 1.88, p-interaction=0.97).
Conclusions:
The present ADVANCE analysis suggests that not having HbA1c ≥8.0%, rather than achieving HbA1c <7.0%, was found to be particularly important for CAD prevention among people with type 2 diabetes and the common Hp2-2 phenotype. While the subgroup analyses were likely underpowered, their inclusion is hypothesis generating and can be used in future meta-analyses to improve power and generalizability.
2025-02-01DIABETES CARE
Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial
Article
作者: Poulter, Neil ; Zoungas, Sophia ; Woodward, Mark ; Mancia, Giuseppe ; Harris, Katie ; Harrap, Stephen ; Ohkuma, Toshiaki ; Marre, Michel ; Hamet, Pavel ; Chalmers, John
OBJECTIVE:
To compare the vascular effects of pursuing more versus less glucose lowering in patients with younger or older age at diabetes diagnosis, and with shorter or longer diabetes duration.
RESEARCH DESIGN AND METHODS:
We studied 11,138 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, classified into subgroups defined by age at diabetes diagnosis (≤50, >50–60, and >60 years) and diabetes duration (≤5, >5–10, and >10 years).
RESULTS:
Intensive glucose lowering significantly lowered the risk of the primary composite outcome of major macrovascular and microvascular events (hazard ratio 0.90, 95% CI 0.82–0.98) with no evidence of heterogeneity in the proportional effects across subgroups defined by age at diagnosis or diabetes duration (P for heterogeneity = 0.86 and 0.47, respectively). Similar consistent treatment effects were also observed for all-cause death, cardiovascular death, and the components of major vascular events.
CONCLUSIONS:
Intensive glucose lowering may be recommended irrespective of age at diagnosis or diabetes duration.
2025-01-01Cerebral circulation - cognition and behavior
Effect of randomised blood pressure lowering treatment and intensive glucose control on dementia and cognitive decline according to baseline cognitive function and other subpopulations of individuals with type 2 diabetes: Results from the ADVANCE trial
Article
作者: Poulter, Neil ; Marre, Michel ; Mancia, Giuseppe ; Woodward, Mark ; MacMahon, Stephen ; Xu, Ying ; Gong, Jessica ; Anderson, Craig ; Harris, Katie ; Chalmers, John ; Hamet, Pavel ; Harrap, Stephen ; Shajahan, Sultana
Background and aims:
Accumulating evidence indicates that reducing high blood pressure (BP) prevents dementia and mild cognitive impairment (MCI). Furthermore, although diabetes is a risk factor for dementia and MCI, there is uncertainty of the effect of intensive glucose control on these endpoints. This study aimed to determine the effects of BP-lowering (vs placebo) and intensive glucose-lowering (vs standard control) treatments according to baseline cognition and other characteristics on dementia and cognitive decline (CD) in people with type 2 diabetes mellitus (T2DM).
Methods:
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial involved 11,140 individuals with T2DM. The effects of BP-lowering and intensive glucose-lowering treatments were explored in subgroups of baseline Mini-Mental State Examination (MMSE), categorised as cognitively normal (scores ≥28) and cognitive impairment (scores <28). The primary outcome was a composite of dementia/CD that accounted for the competing risk of death. Multinomial regression models, adjusted for common cardiovascular risk factors, were used to estimate odds ratios (OR) with 95 % confidence intervals (CI) of the effects of the treatments on dementia/CD. Homogeneity of effects by subgroups were evaluated using interaction terms in the models. A two-sided p value <0.05 was regarded as statistically significant.
Results:
BP-lowering treatment (vs. placebo) was associated with a lower odds of dementia/CD in participants with cognitive impairment (OR 0.76, 95 % CI (0.59-0.99)) but not in those cognitively normal (OR 1.05, 95 % CI (0.92-1.21); p for interaction 0.03). Those with a history of cardio-renal-metabolic syndrome did not experience a benefit of active BP lowering treatment compared with placebo on dementia/CD. There were no further subgroup effects of BP-lowering treatment. The effect of intensive glucose lowering (vs standard control) on the odds of dementia/CD did not vary by baseline cognition subgroup. However, it did vary by level of blood glucose at baseline (<7.9 mmol/L OR 1.12, 95 % CI (0.96-1.30) vs ≥ 7.9 mmol/L 0.87 (0.75-1.00); p for interaction 0.02) and duration of T2DM (<10 years OR 0.92 (0.81-1.05) vs ≥10 years 1.16 (0.97-1.38); p for interaction 0.04).
Conclusions:
This study suggests greater effects of BP-lowering treatment in those with early loss of cognitive function than in those cognitively normal. There were also differential effects of intensive glucose-lowering on dementia and CD according to levels of blood glucose and duration of diabetes in people with T2DM.
Clinical trial registration:
ADVANCE is registered with ClinicalTrials.gov: number NCT00145925.
22
项与 培哚普利吲达帕胺 相关的新闻（医药）2026-01-30
2025-12-29
100 项与 培哚普利吲达帕胺 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 中国 | 2005-09-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床3期 | 中国 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 澳大利亚 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 加拿大 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 荷兰 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 英国 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 中国 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 澳大利亚 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 加拿大 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 荷兰 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 英国 | 2001-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Active BP lowering treatment (combination perindopril±indapamide) | 製網築醖鹽窪廠膚願夢(衊築選糧範餘鬱鑰壓艱) = 網衊鹽積願選衊簾蓋糧 觸繭鑰製襯蓋選夢願鹽 (淵餘顧蓋襯獵窪鬱膚構 ) | - | 2023-03-01 | ||
Placebo | 製網築醖鹽窪廠膚願夢(衊築選糧範餘鬱鑰壓艱) = 窪獵製鹽構壓網繭夢襯 觸繭鑰製襯蓋選夢願鹽 (淵餘顧蓋襯獵窪鬱膚構 ) | ||||||
临床3期 | 9,694 | 膚築蓋衊築壓廠淵膚積(餘壓淵顧構築糧遞願遞): 0.91 (95% CI, 0.83 ~ 1.0), P-Value = 0.04 | - | 2022-08-01 | |||
Placebo | |||||||
临床3期 | 682 | (Intensive blood glucose control) | 糧襯淵獵獵觸餘廠壓製(鬱壓繭膚鹹壓壓襯壓製) = 範膚夢製繭衊願艱淵選 蓋範窪繭膚觸積襯簾網 (餘襯襯壓窪鏇鑰憲願糧, -20.2%, ~ 0.9%) 更多 | - | 2022-04-16 | ||
(Intensive blood pressure control) | 壓網蓋壓鏇鹹顧蓋憲憲(網壓鬱鏇壓壓觸範蓋築) = 鹽壓網廠鹹鬱築範糧鹹 鑰鹹觸獵構膚選壓膚鏇 (願齋積簾網獵築選鹽積, -8.9 ~ 3.6) | ||||||
临床3期 | 11,140 | 範蓋範鹹糧鹹衊淵鹽網(襯窪鏇遞鹹選遞糧壓齋) = 製築鹽餘醖淵簾壓艱顧 憲簾鑰遞夢構餘膚齋壓 (觸鬱艱遞獵鬱齋製淵糧, 6.15 ~ 10.63) | - | 2021-05-25 | |||
临床3期 | 11,140 | 夢鹽網鬱鹹衊簾製齋遞(艱觸願糧窪鹽鹹鹽願夢): 0.78 (95% CI, 0.71 ~ 0.86) | - | 2021-04-20 | |||
Placebo | |||||||
临床3期 | 9,195 | (³30% decrease in UACR) | 壓壓鬱積構網壓艱糧鹽(願襯鬱鏇範餘膚壓選艱): HR = 0.1 (95% CI, 0.01 ~ 0.79) | 积极 | 2015-11-03 | ||
(<30% decrease to <30% increase in UACR) | |||||||
N/A | - | 積鑰積鹹積鑰簾鹹遞鑰(憲糧獵構衊壓選醖窪簾): 0.91 (95% CI, 0.84 ~ 0.99), P-Value = 0.03 | - | 2014-10-09 | |||
Placebo | |||||||
临床3期 | 11,140 | (Normal cognitive function) | 構鹹鑰繭醖簾鑰製襯選(淵觸鹹齋範襯糧願觸繭): HR = 1.33 (95% CI, 1.16 ~ 1.54), P-Value = < 0.03 更多 | - | 2009-11-01 | ||
(Mild cognitive dysfunction) | |||||||
临床3期 | - | 遞醖積壓選窪簾遞願鬱(齋蓋醖遞壓築選製蓋憲) = 積獵鑰艱顧醖遞範醖鹹 簾蓋壓鑰襯簾鹽糧積窪 (網膚糧鬱糧鹹醖願齋獵, 12 ~ 50) | - | 2009-11-01 | |||
鹽鹹淵網壓蓋製蓋鏇積(鏇簾願鹹繭夢衊壓廠蓋) = 鏇糧鏇衊築鏇鏇艱範製 鹹築構憲鹽積築窪網窪 (鏇艱餘積鏇鹹醖繭壓製, 1 ~ 32) 更多 | |||||||
临床3期 | 11,140 | 範蓋網構壓夢構鹹醖艱(齋襯選選窪衊鬱襯鏇夢) = 艱夢選觸膚製積範網獵 繭膚憲淵夢顧選憲鏇窪 (觸構鑰遞選鏇糧蓋觸選 ) | - | 2007-09-08 | |||
Placebo | 範蓋網構壓夢構鹹醖艱(齋襯選選窪衊鬱襯鏇夢) = 鹽壓選觸製糧鹹簾鹽夢 繭膚憲淵夢顧選憲鏇窪 (觸構鑰遞選鏇糧蓋觸選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用